[go: up one dir, main page]

FR22C1005I1 - NEW ALPHA2 ADRENERGIC RECEPTOR AGONISTS - Google Patents

NEW ALPHA2 ADRENERGIC RECEPTOR AGONISTS

Info

Publication number
FR22C1005I1
FR22C1005I1 FR22C1005C FR22C1005C FR22C1005I1 FR 22C1005 I1 FR22C1005 I1 FR 22C1005I1 FR 22C1005 C FR22C1005 C FR 22C1005C FR 22C1005 C FR22C1005 C FR 22C1005C FR 22C1005 I1 FR22C1005 I1 FR 22C1005I1
Authority
FR
France
Prior art keywords
new
receptor agonists
adrenergic receptor
alpha2 adrenergic
alpha2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1005C
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR22C1005I1 publication Critical patent/FR22C1005I1/en
Application granted granted Critical
Publication of FR22C1005I2 publication Critical patent/FR22C1005I2/en
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR22C1005C 2012-04-02 2022-01-31 NEW ALPHA2 ADRENERGIC RECEPTOR AGONISTS Active FR22C1005I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619109P 2012-04-02 2012-04-02
PCT/FI2013/000013 WO2013150173A1 (en) 2012-04-02 2013-03-28 New alpha2 adrenoceptor agonists

Publications (2)

Publication Number Publication Date
FR22C1005I1 true FR22C1005I1 (en) 2022-03-11
FR22C1005I2 FR22C1005I2 (en) 2024-10-25

Family

ID=48224812

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1005C Active FR22C1005I2 (en) 2012-04-02 2022-01-31 NEW ALPHA2 ADRENERGIC RECEPTOR AGONISTS

Country Status (25)

Country Link
US (1) US9249127B2 (en)
EP (1) EP2834233B1 (en)
JP (1) JP6427096B2 (en)
KR (1) KR102104228B1 (en)
CN (1) CN104220437B (en)
AR (1) AR090557A1 (en)
AU (1) AU2013244859B2 (en)
BR (1) BR112014023957B1 (en)
CA (1) CA2868611C (en)
DK (1) DK2834233T3 (en)
ES (1) ES2674945T3 (en)
FR (1) FR22C1005I2 (en)
HR (1) HRP20181203T1 (en)
HU (2) HUE039290T2 (en)
IL (1) IL234663B (en)
LT (2) LT2834233T (en)
MX (1) MX358429B (en)
NL (1) NL301160I2 (en)
NO (1) NO2022002I1 (en)
PL (1) PL2834233T3 (en)
PT (1) PT2834233T (en)
RU (1) RU2642065C2 (en)
SI (1) SI2834233T1 (en)
TW (1) TWI620746B (en)
WO (1) WO2013150173A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015152196A1 (en) * 2014-03-31 2017-04-13 東レ株式会社 Imidazoline derivatives and their pharmaceutical use
EA201791804A1 (en) * 2015-02-11 2018-02-28 Суновион Фармасьютикалз Инк. COMPOUNDS 1-HETEROCYCLYL ISOHROMANIL AND ANALOGUES FOR THE TREATMENT OF CNS DISORDERS
CN105646306B (en) * 2015-12-11 2020-06-30 广东莱佛士制药技术有限公司 Preparation method of 4-methylthio phenylacetic acid
AU2018376872B2 (en) * 2017-12-01 2023-12-07 Orion Corporation Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 H-imidazole and the hydrogensulfate salt thereof
CN110272407B (en) * 2019-07-22 2021-02-05 河北省农林科学院经济作物研究所 Natural isochromanone compound for reducing blood pressure
AU2022239873A1 (en) * 2021-03-19 2023-11-02 Orion Corporation Tasipimidine formulations and use thereof
US20250179056A1 (en) 2022-01-24 2025-06-05 Orion Corporation Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
KR20240144336A (en) 2022-02-04 2024-10-02 오리온 코포레이션 A novel salt form of an alpha-2A adrenoceptor agonist with isochroman-imidazole structure
AU2023348393A1 (en) 2022-09-28 2025-05-01 Orion Corporation Tasipimidine and cyp2d6 inhibitor combination treatment
CN117343036A (en) * 2023-03-20 2024-01-05 江苏联环药业股份有限公司 Isochroman compound, and pharmaceutical composition and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1247008B (en) * 1965-10-05 1967-08-10 Huels Chemische Werke Ag Thermoplastic compounds for the production of non-yellowing, anti-static molded articles made of polyolefins
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
DE3583900D1 (en) * 1984-06-06 1991-10-02 Abbott Lab ADRENERGIC CONNECTIONS.
IL136388A0 (en) * 1997-12-04 2001-06-14 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
FI20000073A0 (en) * 2000-01-14 2000-01-14 Orion Yhtymae Oy New imidazole derivatives
JP2009524618A (en) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Use of 2-imidazole in the treatment of CNS disorders
ES2338716T3 (en) 2006-01-27 2010-05-11 F.Hoffmann-La Roche Ag USE OF 4-IMIDAZOL DERIVATIVES FOR CNS DISORDERS.
CA2657481A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists

Also Published As

Publication number Publication date
DK2834233T3 (en) 2018-06-18
BR112014023957A8 (en) 2021-06-15
NL301160I2 (en) 2022-04-06
PT2834233T (en) 2018-07-17
IL234663B (en) 2019-07-31
CN104220437A (en) 2014-12-17
JP2015512438A (en) 2015-04-27
LTC2834233I2 (en) 2024-07-10
NO2022002I1 (en) 2022-01-27
WO2013150173A1 (en) 2013-10-10
HK1205115A1 (en) 2015-12-11
IL234663A0 (en) 2014-11-30
PL2834233T3 (en) 2018-09-28
HRP20181203T1 (en) 2018-10-05
CA2868611A1 (en) 2013-10-10
AU2013244859B2 (en) 2017-06-22
FR22C1005I2 (en) 2024-10-25
EP2834233A1 (en) 2015-02-11
EP2834233B1 (en) 2018-04-25
HUE039290T2 (en) 2018-12-28
US9249127B2 (en) 2016-02-02
LT2834233T (en) 2018-06-11
LTPA2022001I1 (en) 2022-02-25
MX358429B (en) 2018-08-20
BR112014023957B1 (en) 2022-03-29
AR090557A1 (en) 2014-11-19
KR102104228B1 (en) 2020-04-27
US20150065550A1 (en) 2015-03-05
MX2014011851A (en) 2014-11-21
AU2013244859A1 (en) 2014-10-02
BR112014023957A2 (en) 2017-06-20
RU2642065C2 (en) 2018-01-24
CN104220437B (en) 2017-11-10
ES2674945T3 (en) 2018-07-05
TWI620746B (en) 2018-04-11
KR20140138826A (en) 2014-12-04
SI2834233T1 (en) 2018-08-31
CA2868611C (en) 2020-07-21
RU2014144284A (en) 2016-05-27
HUS2200005I1 (en) 2016-04-28
TW201400478A (en) 2014-01-01
JP6427096B2 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
FR22C1005I2 (en) NEW ALPHA2 ADRENERGIC RECEPTOR AGONISTS
EP2822843A4 (en) HIKING SADDLE
HUE037666T2 (en) Pyrimidin-2-amides are useful as CB2 agonists
CO6862160A2 (en) Indazoles
EP2836211A4 (en) NEW PROCESSES
EP2925745A4 (en) CXCR7 ANTAGONISTS
EP2846787A4 (en) NEW PROCESSES
DK2928870T3 (en) Neurotensin receptor ligands
DK2776436T3 (en) NEW CONNECTIONS
ES2643056T3 (en) Pyridine-2-amides useful as cb2 agonists
EP2922550A4 (en) NEW COMPOUNDS
DK2758523T3 (en) stromal
DK3312169T3 (en) 5-HT3 RECEPTOR ANTAGONISTS
DK2671011T3 (en) CLAMPING RING
CO6970588A2 (en) Ep1 receptor ligands
EP2922547A4 (en) NEW COMPOUNDS
PL2701614T3 (en) PERFUSION CLAMP
EP2785843A4 (en) NEW ENHANCED SELECTINE ANTAGONISTS
BR112014004742A2 (en) trough
FI20115209L (en) Porosity measurement
DE112012005400A5 (en) saddle
DK2877173T3 (en) Antagonists / inverse agonists for cannabinoid receptors
BR112013032213A2 (en) independent trough
EP2867205A4 (en) NOVEL CHOLECYSTOCININ RECEPTOR LIGANDS
BR112014008222A2 (en) heterocyclylpyri (mi) dinilpyrazole